{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:33:24Z","timestamp":1793082804382,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1430,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1124\/jpet.120.000340","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T02:20:19Z","timestamp":1604974819000},"page":"204-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":198,"title":["The Pharmacological Case for Cannabigerol"],"prefix":"10.1016","volume":"376","author":[{"given":"Rahul","family":"Nachnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley M.","family":"Raup-Konsavage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4902-7733","authenticated-orcid":false,"given":"Kent E.","family":"Vrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000340_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ecco-jcc\/jjy185","article-title":"Cannabis, cannabinoids, and the endocannabinoid system-is there therapeutic potential for inflammatory bowel disease?","volume":"13","author":"Ambrose","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1124\/jpet.120.000340_bib2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1021\/np8002673","article-title":"Antibacterial cannabinoids from Cannabis sativa: a structure-activity study","volume":"71","author":"Appendino","year":"2008","journal-title":"J Nat Prod"},{"key":"10.1124\/jpet.120.000340_bib3","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1586\/ern.10.133","article-title":"The use of \u03b1-2A adrenergic agonists for the treatment of attention-deficit\/hyperactivity disorder","volume":"10","author":"Arnsten","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1124\/jpet.120.000340_bib4","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1523\/JNEUROSCI.08-11-04287.1988","article-title":"The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes","volume":"8","author":"Arnsten","year":"1988","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.120.000340_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/archpsyc.1994.03950030084009","article-title":"Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors","volume":"51","author":"Artigas","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.120.000340_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0166-2236(96)10037-0","article-title":"Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists","volume":"19","author":"Artigas","year":"1996","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.120.000340_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/head.13345","article-title":"Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science","volume":"58","author":"Baron","year":"2018","journal-title":"Headache"},{"key":"10.1124\/jpet.120.000340_bib8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA"},{"key":"10.1124\/jpet.120.000340_bib9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.bcp.2013.01.017","article-title":"Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease","volume":"85","author":"Borrelli","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib10","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/carcin\/bgu205","article-title":"Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid","volume":"35","author":"Borrelli","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1124\/jpet.120.000340_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.mayocp.2011.10.003","article-title":"Blurred boundaries: the therapeutics and politics of medical marijuana","volume":"87","author":"Bostwick","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/jpet.120.000340_bib12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/jcsm.12426","article-title":"Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol","volume":"10","author":"Brierley","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1124\/jpet.120.000340_bib13","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1007\/s00213-016-4397-4","article-title":"Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats","volume":"233","author":"Brierley","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.120.000340_bib14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/FBP.0000000000000285","article-title":"A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats","volume":"28","author":"Brierley","year":"2017","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib15","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.120.000340_bib16","doi-asserted-by":"crossref","first-page":"e94733","DOI":"10.1371\/journal.pone.0094733","article-title":"A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis","volume":"9","author":"Carrillo-Salinas","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.000340_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1476-5381.2009.00515.x","article-title":"Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist","volume":"159","author":"Cascio","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/apt.14226","article-title":"Review article: the many potential roles of intestinal serotonin (5-hydroxytryptamine, 5-HT) signalling in inflammatory bowel disease","volume":"46","author":"Coates","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.120.000340_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0021-9258(19)40195-6","article-title":"Multiple second messenger pathways of alpha-adrenergic receptor subtypes expressed in eukaryotic cells","volume":"265","author":"Cotecchia","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.120.000340_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbagen.2019.01.002","article-title":"Identification and characterization of phytocannabinoids as novel dual PPAR\u03b1\/\u03b3 agonists by a computational and in vitro experimental approach","volume":"1863","author":"D\u2019Aniello","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1124\/jpet.120.000340_bib21","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1748-1716.2011.02338.x","article-title":"Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation","volume":"204","author":"De Petrocellis","year":"2012","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1124\/jpet.120.000340_bib23","doi-asserted-by":"crossref","first-page":"29789","DOI":"10.1038\/srep29789","article-title":"VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington\u2019s disease","volume":"6","author":"D\u00edaz-Alonso","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.120.000340_bib24","doi-asserted-by":"crossref","unstructured":"Echeverry C, Prunell G, Narbondo C, de Medina VS, Nadal X, Reyes-Parada M and Scorza C (2020) A Comparative in vitro study of the neuroprotective effect induced by cannabidiol, cannabigerol, and their respective acid forms: relevance of the 5-HT. Neurotox Res. doi: 10.1007\/s12640-020-00277-y. [published ahead of print].","DOI":"10.1007\/s12640-020-00277-y"},{"key":"10.1124\/jpet.120.000340_bib25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-3565(25)12477-4","article-title":"Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla","volume":"253","author":"Ernsberger","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000340_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/acsinfecdis.9b00419","article-title":"Uncovering the hidden antibiotic potential of cannabis","volume":"6","author":"Farha","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1124\/jpet.120.000340_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00213-012-2697-x","article-title":"Cannabinol and cannabidiol exert opposing effects on rat feeding patterns","volume":"223","author":"Farrimond","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.120.000340_bib28","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1046\/j.1432-1327.2001.02030.x","article-title":"Biosynthesis of cannabinoids. Incorporation experiments with (13)C-labeled glucoses","volume":"268","author":"Fellermeier","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1124\/jpet.120.000340_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0014-5793(98)00450-5","article-title":"Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol","volume":"427","author":"Fellermeier","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.120.000340_bib30","doi-asserted-by":"crossref","first-page":"113859","DOI":"10.1016\/j.bcp.2020.113859","article-title":"Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets","volume":"175","author":"Fellous","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12974-018-1060-5","article-title":"Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson\u2019s disease: possible involvement of different binding sites at the PPAR\u03b3 receptor","volume":"15","author":"Garc\u00eda","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1124\/jpet.120.000340_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/08998280.2001.11927725","article-title":"Dexmedetomidine: a novel sedative-analgesic agent","volume":"14","author":"Gertler","year":"2001","journal-title":"Proc Bayl Univ Med Cent"},{"key":"10.1124\/jpet.120.000340_bib33","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11481-012-9399-3","article-title":"A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis","volume":"7","author":"Granja","year":"2012","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib34","first-page":"227","article-title":"The transcriptomic analysis of NSC-34 motor neuron-like cells reveals that cannabigerol influences synaptic pathways: a comparative study with cannabidiol","volume":"10","author":"Gugliandolo","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1124\/jpet.120.000340_bib35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.tplants.2020.05.005","article-title":"Phytocannabinoids: origins and biosynthesis","volume":"25","author":"G\u00fclck","year":"2020","journal-title":"Trends Plant Sci"},{"key":"10.1124\/jpet.120.000340_bib36","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/sj.bjp.0701520","article-title":"Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice","volume":"122","author":"Hunter","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000340_bib38","series-title":"Phytocannabinoids","author":"Kinghorn","year":"2017"},{"key":"10.1124\/jpet.120.000340_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000507998","article-title":"Delta-9-Tetrahydrocannabinol and cannabidiol drug-drug interactions","volume":"3","author":"Kocis","year":"2020","journal-title":"Med Cannabis Cannabinoids"},{"key":"10.1124\/jpet.120.000340_bib40","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/medicina55110747","article-title":"Could the combination of two non-psychotropic cannabinoids counteract neuroinflammation? Effectiveness of cannabidiol associated with cannabigerol","volume":"55","author":"Mammana","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"Suppl 2","key":"10.1124\/jpet.120.000340_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198400282-00002","article-title":"Alpha- and beta-adrenergic receptor subtypes properties, distribution and regulation","volume":"28","author":"Molinoff","year":"1984","journal-title":"Drugs"},{"key":"10.1124\/jpet.120.000340_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid ligands targeting TRP channels","volume":"11","author":"Muller","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.1124\/jpet.120.000340_bib43","doi-asserted-by":"crossref","first-page":"104940","DOI":"10.1016\/j.phrs.2020.104940","article-title":"Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1\/CB2 heteromer receptors","volume":"159","author":"Navarro","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1124\/jpet.120.000340_bib44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fphar.2018.00632","article-title":"Cannabigerol action at cannabinoid CB 1 and CB 2 receptors and at CB 1-CB 2 heteroreceptor complexes","volume":"9","author":"Navarro","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib45","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","article-title":"Serotonin receptors","volume":"108","author":"Nichols","year":"2008","journal-title":"Chem Rev"},{"key":"10.1124\/jpet.120.000340_bib46","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","author":"O\u2019Sullivan","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib47","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.imbio.2009.09.007","article-title":"Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease","volume":"215","author":"O\u2019Sullivan","year":"2010","journal-title":"Immunobiology"},{"key":"10.1124\/jpet.120.000340_bib48","doi-asserted-by":"crossref","unstructured":"Pagano E, Iannotti FA, Piscitelli F, Romano B, Lucariello G, Venneri T, Di Marzo V, Izzo AA and Borrelli F (2020) Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. Phytother Res. DOI: 10.1002\/ptr.6831 [published ahead of print].","DOI":"10.1002\/ptr.6831"},{"key":"10.1124\/jpet.120.000340_bib49","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/molecules23051230","article-title":"Quality traits of \u201ccannabidiol oils\u201d: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations","volume":"23","author":"Pavlovic","year":"2018","journal-title":"Molecules"},{"key":"10.1124\/jpet.120.000340_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib51","doi-asserted-by":"crossref","first-page":"R287","DOI":"10.1152\/ajpregu.00123.2002","article-title":"Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough","volume":"283","author":"Philipp","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.120.000340_bib52","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3390\/molecules24142567","article-title":"In silico repositioning of cannabigerol as a novel inhibitor of the enoyl Acyl Carrier Protein (ACP) reductase (InhA)","volume":"24","author":"Pinzi","year":"2019","journal-title":"Molecules"},{"key":"10.1124\/jpet.120.000340_bib53","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1021\/np200500p","article-title":"Bioactive prenylogous cannabinoid from fiber hemp (Cannabis sativa)","volume":"74","author":"Pollastro","year":"2011","journal-title":"J Nat Prod"},{"key":"10.1124\/jpet.120.000340_bib54","doi-asserted-by":"crossref","DOI":"10.1159\/000510256","article-title":"Cannabidiol (CBD) oil does not display an entourage effect in reducing cancer cell viability in vitro","author":"Raup-Konsavage","year":"2020","journal-title":"Med Cannabis Cannabinoids"},{"key":"10.1124\/jpet.120.000340_bib55","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","article-title":"Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus","volume":"165","author":"Rock","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib56","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-010-2157-4","article-title":"Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews","volume":"215","author":"Rock","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.120.000340_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bcp.2018.07.049","article-title":"Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1 G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis","volume":"157","author":"Rodr\u00edguez-Cueto","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib58","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fncel.2016.00272","article-title":"What do we really know about 5-HT 1A receptor signaling in neuronal cells?","volume":"10","author":"Rojas","year":"2016","journal-title":"Front Cell Neurosci"},{"key":"10.1124\/jpet.120.000340_bib59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ntt.2014.09.003","article-title":"Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures","volume":"46","author":"Rosenthaler","year":"2014","journal-title":"Neurotoxicol Teratol"},{"key":"10.1124\/jpet.120.000340_bib60","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.tips.2016.04.005","article-title":"Beyond cannabis: plants and the endocannabinoid system","volume":"37","author":"Russo","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.120.000340_bib61","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem Res"},{"key":"10.1124\/jpet.120.000340_bib62","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000340_bib63","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/can.2017.0028","article-title":"Cannabis roots: a traditional therapy with future potential for treating inflammation and pain","volume":"2","author":"Ryz","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1124\/jpet.120.000340_bib64","series-title":"Drug enforcement in the United States: history, policy, and trends","author":"Sacco","year":"2014"},{"key":"10.1124\/jpet.120.000340_bib65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0163-7258(99)00032-7","article-title":"Localization and trafficking of alpha2-adrenergic receptor subtypes in cells and tissues","volume":"84","author":"Saunders","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.120.000340_bib66","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/S0031-9422(00)91096-3","article-title":"Biosynthesis of cannabinoid acids","volume":"14","author":"Shoyama","year":"1975","journal-title":"Phytochemistry"},{"key":"10.1124\/jpet.120.000340_bib67","first-page":"pyu094","article-title":"Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers","volume":"18","author":"Tudge","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/jpet.120.000340_bib68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/nu12020357","article-title":"Potency assessment of CBD oils by their effects on cell signaling pathways","volume":"12","author":"Urasaki","year":"2020","journal-title":"Nutrients"},{"key":"10.1124\/jpet.120.000340_bib69","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fpsyt.2017.00144","article-title":"Therapeutic potential of selectively targeting the \u03b1 2C-adrenoceptor in cognition, depression, and schizophrenia-new developments and future perspective","volume":"8","author":"Uys","year":"2017","journal-title":"Front Psychiatry"},{"key":"10.1124\/jpet.120.000340_bib70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","article-title":"Neuroprotective properties of cannabigerol in Huntington\u2019s disease: studies in R6\/2 mice and 3-nitropropionate-lesioned mice","volume":"12","author":"Valdeolivas","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1124\/jpet.120.000340_bib71","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000340_bib72","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/0024-3205(80)90631-1","article-title":"Anti-inflammatory properties of cannabichromene","volume":"26","author":"Wirth","year":"1980","journal-title":"Life Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:53:12Z","timestamp":1740675192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0022356524257438"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000340","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pharmacological Case for Cannabigerol","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Author(s)","name":"copyright","label":"Copyright"}]}}